<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05082584</url>
  </required_header>
  <id_info>
    <org_study_id>AKB-6548-CI-0042</org_study_id>
    <nct_id>NCT05082584</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents</brief_title>
  <acronym>CORRECTION</acronym>
  <official_title>A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of Once Daily Oral Vadadustat for The Treatment of Pediatric Subjects With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-stimulating Agents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akebia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akebia Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of once daily dosing of vadadustat for the&#xD;
      treatment of pediatric participants with anemia of chronic kidney disease (CKD) naive to&#xD;
      erythropoiesis-stimulating agent (ESA) treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Hemoglobin (Hb) Values Between Baseline and the Primary Evaluation Period (Average Hb From Weeks 21 to 28)</measure>
    <time_frame>Baseline; Weeks 21 to 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Achieve First Hb Levels ≥10.0 grams/deciliters (g/dL)</measure>
    <time_frame>Up to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mean Hb Values Within the Target Range During the Primary Evaluation Period</measure>
    <time_frame>From Week 21 to Week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mean Hb Values Within the Target Range During the Extension Period</measure>
    <time_frame>From Week 29 to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events and who Discontinued From the Study due to Adverse Events</measure>
    <time_frame>Up to Week 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Vadadustat and its Metabolites</measure>
    <time_frame>Pre-dose and post-dose at intermediate time points up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From 0 to Last Quantifiable Concentration (AUC 0-t) of Vadadustat and its Metabolites</measure>
    <time_frame>Pre-dose and post-dose at intermediate time points up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Cmax (Tmax) of Vadadustat and its Metabolites</measure>
    <time_frame>Pre-dose and post-dose at intermediate time points up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-Life (t1/2) of Vadadustat and its Metabolites</measure>
    <time_frame>Pre-dose and post-dose at intermediate time points up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Erythropoietin (EPO)</measure>
    <time_frame>Pre-dose and post-dose at intermediate time points up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Reticulocyte Count</measure>
    <time_frame>Pre-dose and post-dose at intermediate time points up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hb levels</measure>
    <time_frame>Pre-dose and post-dose at intermediate time points up to 28 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">71</enrollment>
  <condition>Anemia of Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Vadadustat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: participants with ≥12 years to &lt;17 years; Cohort 2: participants with ≥6 years to &lt;12 years; Cohort 3(a): participants with ≥2 years to &lt;6 years; and Cohort 3(b): participants with ≥4 months to &lt;2 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vadadustat</intervention_name>
    <description>Vadadustat tablet orally once a day for 52 weeks</description>
    <arm_group_label>Vadadustat</arm_group_label>
    <other_name>AKB-6548</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of anemia of chronic kidney disease (CKD)&#xD;
&#xD;
          -  Diagnosis of non-dialysis-dependent (NDD) CKD with an estimated glomerular filtration&#xD;
             rate of greater than (&gt;) 10 and less than (&lt;) 60 milliliters/minute/1.73 meters^2&#xD;
             (mL/min/1.73 m^2 ) or diagnosis of dialysis dependent (DD) CKD&#xD;
&#xD;
          -  Mean screening hemoglobin (Hb) &lt;10.0 grams/deciliters (g/dL)&#xD;
&#xD;
          -  Transferrin Saturation ≥ 20%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Anemia due to a cause other than CKD&#xD;
&#xD;
          -  Active bleeding or recent clinically significant blood loss&#xD;
&#xD;
          -  Treatment with an erythropoiesis-stimulating agents (ESA) within 8 weeks prior to&#xD;
             Screening&#xD;
&#xD;
          -  History of sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis,&#xD;
             hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell&#xD;
             aplasia&#xD;
&#xD;
          -  Red Blood Cells transfusion within 4 weeks&#xD;
&#xD;
          -  Serum albumin level &lt;2.5 g/dL&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Active malignancy or treatment for malignancy within the past 2 years prior to&#xD;
             Screening&#xD;
&#xD;
          -  Evidence of iron overload or diagnosis of hemochromatosis&#xD;
&#xD;
          -  Known hypersensitivity to vadadustat or any excipients in vadadustat tablet&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Months</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Akebia Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Akebia Therapeutics, Inc.</last_name>
    <phone>617-844-6128</phone>
    <email>trials@akebia.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anemia</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>erythropoiesis stimulating agent</keyword>
  <keyword>dialysis</keyword>
  <keyword>vadadustat</keyword>
  <keyword>pediatric population</keyword>
  <keyword>children</keyword>
  <keyword>kidney disease</keyword>
  <keyword>hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

